SCHEMBL5877201

SCHEMBL5877201

Cc1ccc(S(=O)(=O)n2nc(NC3CC3)c3c2CC(c2ccccc2)(C2CCCCC2)C=C3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
HTR6 P50406 3/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 7/20 0.33
KMT2A Q03164 2/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
GLA P06280 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
FPR1 P21462 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
EPHX2 P34913 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877353 0.97 NOD2 (0.36) NOD2NOD1HTR6MAPTALDH1A1
SCHEMBL5875979 0.90 ALDH1A1 (0.34) MAPTALDH1A1KMT2AGLANR1H2
SCHEMBL5876012 0.87 NR1H2 (0.36) NOD2NOD1MAPTALDH1A1KMT2A
SCHEMBL5876198 0.86 USP2 (0.37) NOD2NOD1HTR6ALDH1A1KMT2A
SCHEMBL5876614 0.86 ALDH1A1 (0.39) NOD2NOD1MAPTALDH1A1KMT2A
SCHEMBL5877598 0.85 CYP2C19 (0.36) MAPTALDH1A1KMT2AUSP2MAPK1
SCHEMBL5877844 0.84 ALDH1A1 (0.38) MAPTALDH1A1KMT2AUSP2MAPK1
SCHEMBL5876220 0.83 NR1H2 (0.34) ALDH1A1KMT2AUSP2MAPK1NR1H2
SCHEMBL5876490 0.83 USP2 (0.36) NOD2NOD1HTR6ALDH1A1KMT2A
SCHEMBL5876984 0.83 GPR6 (0.35) MAPTALDH1A1KMT2AUSP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT NOD2 2843/4885NOD1 2416/4885HTR6 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.